Anyone actually stuck with Dutasteride after switching from Finasteride? 7/13/2023
The conversation discusses switching from finasteride to dutasteride for hair loss treatment, with mixed experiences regarding shedding and effectiveness. Some users also mention using minoxidil and RU58841 alongside these treatments.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity Topical Finasteride reduced my DHT more than Oral Dutasteride
Treatments for hair loss, including the experiences of topical finasteride and oral dutasteride. It also discusses Pyrilutamide, 0.025% topical concentration, Minoxidil, RU58841, and 1% finasteride gel dosage.
community Changes in Scalp DHT when switching from Finasteride to Dutasteride: detailed video
Switching from finasteride to dutasteride can reduce scalp DHT levels more effectively. The discussion includes using minoxidil, finasteride, and RU58841 for hair loss treatment.
community 21M - 8 months on oral minoxidil, crown still thinning. Considering fin - thoughts?
The conversation suggests starting finasteride or dutasteride alongside minoxidil for better hair loss treatment, as minoxidil alone is seen as ineffective without a DHT blocker. Some users also mention considering RU58841 as an alternative to finasteride.
community Finasteride and Topical Minoxidil to Dutasteride and Oral Minoxidil. Is RU58841 still helping?
The user switched from finasteride and topical minoxidil to dutasteride and oral minoxidil, questioning the effectiveness and safety of continuing RU58841. They experienced hair loss improvement initially but are now considering stopping RU58841 due to cost and safety concerns.
community Dutasteride 0.5 mg/day lowers scalp DHT levels by only 50% (but 2.5 mg/day lowers scalp DHT by 80%).
Dutasteride at 2.5 mg/day reduces scalp DHT by 80%, while 0.5 mg/day reduces it by 50%, with minimal difference in side effects. Users often combine it with finasteride, RU58841, and minoxidil for better hair loss management, though side effects like dry skin and pimples are noted.
community 1 Month RU58841 + Minoxidil + Weekly microneedle
The user is using RU58841, Minoxidil, and weekly microneedling for hair loss, having stopped finasteride due to side effects like low libido and depression. They are considering dutasteride as an alternative but are cautious due to past experiences with DHT blockers.
Related Research
6 / 6 results
research CLINICAL UPDATES IN HAIR
This chapter reviews various antiandrogens and androgen inhibitors, detailing their mechanisms, uses, and side effects, with a focus on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Antiandrogens and Androgen Inhibitors
This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Potential targets in the discovery of new hair growth promoters for androgenic alopecia
This review discusses current therapeutic targets and treatments for androgenic alopecia but reports no clinical results; the authors highlight the challenge of developing multi-target drugs for effective treatment.
research ANDROGENIC ALOPECIA: PATHOGENETIC MECHANISMS AND THERAPEUTIC APPROACHES
This review discusses treatments for androgenic alopecia, noting that current options like finasteride and minoxidil are effective for only 10% of patients, thus highlighting the need for new therapies.
research The role of androgen and androgen receptor in skin-related disorders
This review discusses the roles of androgens and androgen receptors in skin-related disorders and suggests that targeting androgen receptors may be a more effective treatment strategy.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.